GenSight Biologics S.A.: GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ in the US

December 2, 2021, at 8:00 am EST 2:00 pm CET Connection details for live call and translation provided Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME

Related Keywords

Louisiana ,United States ,New Orleans ,Paris ,France General ,France ,French ,American ,James Palmer ,Gensight Biologics Euronext ,Seanp Donahue ,Gensight Biologics ,Thomas Gidoin ,Guillaume Van Renterghem ,Jeanene Timberlake ,Clinical Affairs ,European Union ,European Medicines Agency ,Vanderbilt University ,Meeting Of The American Academy Ophthalmology ,Sight Biologics ,Leber Hereditary Optic Neuropathy ,American Academy ,Coleman Professor ,Vice Chair ,Pediatric Ophthalmology Department ,Vanderbilt Children ,Sight Biologic ,Mitochondrial Targeting Sequence ,Gensight Biologic ,Hereditary Optic Neuropathy ,Institut De La Vision ,Adeno Associated Virus ,Financial Officer ,Gensight ,Iologics ,Most ,Opinion ,Leader ,Ebcast ,Outcomes ,Mong ,Compassionate ,Patients ,Reated ,Unilaterally ,Umevoq ,